← Russell 3000 cross-section

PROK PROKIDNEY CORP.

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Healthcare

Scale

Market cap
$355m
Revenue TTM
$1m
Net income TTM
$-84m
Free cash flow
$-160m
Composite score
Sector rank
#2570

Valuation

P / E
EV / EBITDA
EV / sales
342.5
FCF yield
-45.00%
Earnings yield vs 10-yr
-28.45pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-10,288.4%
EBITDA margin
-20,827.6%
ROE
9.5%
ROIC
Revenue growth

Insider activity, last 90 days

Net open-market
$-1.07m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

General and administrative expenses The decrease in general and administrative expenses of approximately $1.6 million was primarily driven by the following: • decreases in equity-based compensation of approximately $0.6 million due to the completion of vesting for legacy profit interests awards issued prior to the business combination and forfeitures of awards; • decreases in cash-based compensation of approximately $0.6 million related to reductions in severance amounts paid for terminated employees; and • decreases in professional fees and other operating costs of approximately $0.4 million driven by ongoing initiatives including the Domestication and Restructuring transactions in 2025. …PROKIDNEY CORP., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →